← ANALYST RATINGS · TIPRANKS
MoonLake Immunotherapeutics (MLTX): analyst forecast and price target
Analyst consensus
Strong Buy8 Buy1 Hold0 Sell
Ratings of 9 analysts in the last 3 months12-month forecast
Based on 9 price targets given in the last 3 months, the average target is $33.00, the highest $50.00, the lowest $17.00. The average is +245.5% from the last price of $9.55.
Analyst ratings 16
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $10.00 → $10.50+5.0% | Hold | +9.9% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% | RBC Capital | $17.00 | Hold | +78.0% | Reiterated | 16.10.26on TipRanks 10:35 | −5.8% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $10.50 → $10.00−4.8% | Hold | +4.7% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $10.50 → $10.00−4.8% | Hold | +4.7% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $10.00 → $9.50−5.0% | Sell | −0.5% | Downgrade | 15.10.26on TipRanks 16:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $10.50 → $10.00−4.8% | Hold | +4.7% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $11.00 → $10.00−9.1% | Hold | +4.7% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| Yun Zhong★★★★★★★★★★#12228 · hits 38% · avg −9.6% | Wedbush | $34.00 | Buy | +256.0% | Reiterated | 05.10.26on TipRanks 07:56 | −0.9%next day −4.3% · 5 days −6.6% | ↗ |
| Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% | H.C. Wainwright | $50.00 | Buy | +423.6% | Reiterated | 05.10.26on TipRanks 06:55 | −0.9%next day −4.3% · 5 days −6.6% | ↗ |
| Phil Nadeau★★★★★★★★★★#1350 · hits 48% · avg +8.7% | TD Cowen | — | Buy | — | Reiterated | 01.10.26on TipRanks 13:55 | −2.1%next day −1.3% · 5 days −9.1% | ↗ |
| Thomas Smith★★★★★★★★★★#45 · hits 57% · avg +51.1% | Leerink Partners | $30.00 | Buy | +214.1% | Reiterated | 01.10.26on TipRanks 13:55 | −2.1%next day −1.3% · 5 days −9.1% | ↗ |
| Rami Katkhuda★★★★★★★★★★#297 · hits 55% · avg +31.7% | LifeSci Capital | $33.00 | Buy | +245.5% | Reiterated | 30.09.26on TipRanks 18:55 | −2.1%next day −1.3% · 5 days −9.1% | ↗ |
| Julian Harrison★★★★★★★★★★#42 · hits 57% · avg +53.4% | BTIG | $30.00 | Buy | +214.1% | Reiterated | 10.08.26on TipRanks Aug 11 07:10 | −5.1%next day −3.9% · 5 days −5.6% | ↗ |
| Unknown Analyst | Guggenheim | $40.00 | Buy | +318.8% | Reiterated | 10.08.26on TipRanks Aug 11 07:10 | −5.1%next day −3.9% · 5 days −5.6% | ↗ |
| Serge Belanger★★★★★★★★★★#674 · hits 49% · avg +14.9% | Needham | $30.00 | Buy | +214.1% | Reiterated | 10.08.26on TipRanks 12:55 | −5.1%next day −3.9% · 5 days −5.6% | ↗ |
| Kaveri Pohlman★★★★★★★★★★#1640 · hits 40% · avg +12.9% | Clear Street | $70.00 | Buy | +633.0% | Reiterated | 22.06.26on TipRanks 13:50 | +15.7%next day −2.8% · 5 days −9.7% | ↗ |
| Richard Law CFA★★★★★★★★★★#3237 · hits 50% · avg +9.1% | Goldman Sachs | $11.00 → $12.00+9.1% | Sell | +25.7% | Reiterated | 11.05.26on TipRanks 07:50 | +10.2%next day −3.3% · 5 days −12.7% | ↗ |
| Andy Chen★★★★★★★★★★#959 · hits 67% · avg +28.8% | Wolfe Research | $12.00 → $24.00+100.0% | Buy | +151.3% | Upgrade | 23.03.26on TipRanks 05:50 | +2.6%next day −0.6% · 5 days +3.9% | ↗ |
| Samantha Semenkow★★★★★★★★★★#6889 · hits 47% · avg +0.7% | Citi | $6.00 | Sell | −37.2% | Reiterated | 20.03.26on TipRanks 06:50 | −1.0%next day +2.6% · 5 days +8.7% | ↗ |
| Qize Ding★★★★★★★★★★#7161 · hits 67% · avg +5.5% | Rothschild & Co Redburn | $12.00 → $40.00+233.3% | Buy | +318.8% | Upgrade | 19.03.26on TipRanks 04:55 | +3.0%next day −1.0% · 5 days +8.4% | ↗ |
| Alex Thompson CFA★★★★★★★★★★#60 · hits 73% · avg +50.6% | Stifel Nicolaus | $13.00 → $19.00+46.2% | Hold | +99.0% | Reiterated | 01.03.26on TipRanks 14:10 | +0.9%next day +0.9% · 5 days +4.8% | ↗ |
| Prakhar Agrawal★★★★★★★★★★#1817 · hits 40% · avg +16.0% | Cantor Fitzgerald | — | Buy | — | Reiterated | 04.12.25on TipRanks 15:50 | +12.3%next day −0.9% · 5 days −6.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering MoonLake Immunotherapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $33.00 at a price of $11.70 (+182.1%); now: $33.00 at $9.55 (+245.5%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 19 | 18 | 17 | 15 | 8 | 10 |
| Buy | 5 | 5 | 4 | 4 | 1 | 2 |
| Hold | 3 | 2 | 2 | 1 | 1 | 2 |
| Sell | 2 | 1 | 1 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 17.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.78 (from $-0.92 to $-0.66). Last quarter: $-0.84.
Best top-analyst consensus in the sector · Healthcare
About MoonLake Immunotherapeutics
- CEO: Jorge Santos da Silva
- Employees: 130
- Dorfstrasse 29, Zug, ZG, 6300, CH
- www.moonlaketx.com
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
Data from the stock’s TipRanks forecast page, read 61 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗